CogniPrin and FlexiPrin

$6.57 million judgment (partially suspended) / 20-year ban on direct response marketing of food, dietary supplements, or drugs for which a health benefit is claimed / Banned from making claims related to pain relief, cartilage rebuilding, cognitive decline, memory improvement, and disease unless substantiated by competent and reliable scientific evidence that is sufficient in quality and quantity based on standards accepted by experts in the relevant disease, condition, or function to which the representation relates / Such testing shall be randomized, double-blind, and placebo-controlled and conducted by researchers qualified to conduct such testing / Prohibited from misrepresenting any tests or studies, or that a product is proven to reduce pain, improve memory or cognition or provide other benefits / Prohibited from misrepresenting endorsements / Prohibited from misrepresenting that paid advertising is independent or educational programming, or an objective news report / Additional requirements for clear and conspicuous disclosures regarding advertising and purchase conditions